XERAVA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania.

Active ingredients

The drug XERAVA contains one active pharmaceutical ingredient (API):

1	Eravacycline UNII WK1NMH89VJ - ERAVACYCLINE DIHYDROCHLORIDE
	Eravacycline is an antibacterial drug. Its mechanism of action involves the disruption of bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.
	Read more about Eravacycline

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XERAVA Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
XERAVA Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01AA13		J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01A Tetracyclines → J01AA Tetracyclines
Discover more medicines within J01AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1781197, 1813665, 1842106, 1842117
FR	Base de données publique des médicaments	62654238
IT	Agenzia del Farmaco	047191010, 047191022, 047191034, 047191046, 047191059
LT	Valstybinė vaistų kontrolės tarnyba	1086424, 1088260, 1092142, 1092143, 1092975
PL	Rejestru Produktów Leczniczych	100411958, 100461434
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69479001
US	FDA, National Drug Code	71773-050, 71773-100